Mr. Johnson brings more than 30 years of commercialization and operational experience in the biopharmaceutical industry. Prior to joining Vera, he served as the Chief Commercial Officer at Global Blood Therapeutics (GBT) until it was acquired by Pfizer in 2022, during which time he established the company’s global commercial functions and led the launch of Oxbryta.
Prior to GBT, Mr. Johnson spent 15 years at Gilead Sciences, Inc., in roles of increasing responsibility. His most recent position was as Vice President of Sales and Marketing for Gilead’s Liver Disease Business Unit, where he was responsible for building and leading the company’s liver disease franchises, including commercially launching four industry leading medicines to treat hepatitis. Prior to that position, he was Vice President of Sales and Marketing for Gilead’s Antiviral Business Unit, where he helped launch and oversee the HIV franchise.
Mr. Johnson previously had an 11-year tenure at GSK plc, where he held various positions in sales, product marketing, business development, global commercial strategy and portfolio development. Mr. Johnson currently serves on the board of directors of Caribou Biosciences, a public gene therapy company. He received a BA in business marketing from the University of Puget Sound and an MBA from the Kenan-Flagler Business School at the University of North Carolina.
What is David Lee Johnson's net worth?
The estimated net worth of David Lee Johnson is at least $1.87 million as of February 23rd, 2026. Johnson owns 45,727 shares of Vera Therapeutics stock worth more than $1,868,222 as of February 27th. This net worth approximation does not reflect any other investments that Johnson may own. Learn More about David Lee Johnson's net worth.
How do I contact David Lee Johnson?
Has David Lee Johnson been buying or selling shares of Vera Therapeutics?
Within the last three months, David Lee Johnson has sold $108,266.42 of Vera Therapeutics stock. Most recently, David Lee Johnson sold 2,579 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a transaction totalling $108,266.42. Following the completion of the sale, the chief operating officer now directly owns 45,727 shares of the company's stock, valued at $1,919,619.46. Learn More on David Lee Johnson's trading history.
Who are Vera Therapeutics' active insiders?
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, Vera Therapeutics insiders bought shares 3 times. They purchased a total of 255,882 shares worth more than $5,527,583.36. In the last year, insiders at the sold shares 8 times. They sold a total of 48,490 shares worth more than $1,841,810.20. The most recent insider tranaction occured on February, 23rd when insider Robert Brenner sold 2,151 shares worth more than $90,298.98. Insiders at Vera Therapeutics own 16.3% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 2/23/2026.
